Glucagon-like peptide-1 receptor agonists (GLP-1RAs, incretin mimetics) and dipeptidyl
peptidase-4 inhibitors (DPP-4is, incretin enhancers) are glucose-lowering therapies with …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition that
affects nearly one billion people globally, characterized by triacylglycerol accumulation in …

Inflammation is implicated in the development and severity of the coronavirus disease 2019
(COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when …

Diabetic distal symmetric polyneuropathy is the most common type of peripheral neuropathy
complication of diabetes mellitus. Neuroinflammation is emerging as an important …

Background Diabetic peripheral neuropathy (DPN) constitutes a debilitating complication
associated with diabetes. Although, the past decade has seen rapid developments in …

Objective: There is substantial interest in how GLP-1RA (glucagon-like peptide-1 receptor
agonists) and SGLT2 (sodium-glucose cotransporter 2) inhibitors reduce cardiovascular and …

Incretin-based therapies, in particular glucagon-like peptide-1 (GLP-1) receptor agonists,
have been evaluated in other forms of diabetes, but randomised controlled trials are mainly …

Introduction To assess the effect of exenatide and pioglitazone or basal-bolus insulin on
diabetic peripheral neuropathy (DPN) in patients with poorly controlled type 2 diabetes …

The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific
community to breach new frontiers in the understanding of human physiology and disease …

Context Concomitant obesity is common amongst patients with type 1 diabetes mellitus
(T1DM), yet adjunctive therapy options are scarce. Objective We assess the efficacy and …